Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Dare Bioscience, Inc.

NASDAQ: DARE · Life Sciences · 5 alerts · CIK 1401914

Share price
$0.5842Close, Nov 16
Market cap
$11.5M
Shares outstanding
19.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dare Bioscience, Inc. filings on SEC EDGAR ↗

4:09 PM ET 8-K
Financial Results

Dare Bioscience Financial Results

Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.

Term
Q3 2026
4:08 PM ET 10-Q
Financial Results

Dare Bioscience Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.

Key figure
Net loss $3.16M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.